<DOC>
	<DOCNO>NCT02199613</DOCNO>
	<brief_summary>The study aim assess safety efficacy darunavir 800mg plus co-formulated elvitegravir/cobicistat/tenofovir disoproxil fumarate ( DF ) /emtricitabine ( Stribild ) tablet simplification strategy treatment HIV infection HIV-infected subject previous antiretroviral treatment experience multiple-drug regimen . We hypothesize elvitegravir/cobicistat/tenofovir DF/emtricitabine darunavir offer safe efficacious treatment simplification strategy HIV positive patient currently receive multiple-drug regimen control HIV infection .</brief_summary>
	<brief_title>Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy</brief_title>
	<detailed_description>Eligible , consent subject assess baseline week 2 , 12 , 24 , 36 , 48 . Study medication dispense visit except week 2 , participant commence take open-label darunavir 800mg conjunction co-formulated tenofovir DF/emtricitabine/cobicistat/elvitegravir ( Stribild ) tablet , take together daily food , follow study procedure baseline . Assessments study visit include : 1 . Complete physical exam include height weight baseline ; symptom-directed physical exam weight visit 2 . Adverse clinical event include serious adverse event ( hospitalization etc . ) medication change every visit . 3 . HIV RNA every 4 week . 4 . CD4 CD8 absolute count % visit except week 2 . 5 . Platelet count , aspartate amino transferase ( AST ) , creatinine , estimate glomerular filtration rate ( eGFR ) , phosphorus , urinalysis , urine albumin creatinine ratio ( UACR ) visit . 6 . Fasting lipid ( total , HDL , LDL cholesterol triglyceride ) , apolipoprotein B , high-sensitivity C- reactive protein ( hsCRP ) baseline , week 24 , week 48 . 7 . Pregnancy test woman child-bearing potential ( define ) every visit except week 2 . In addition , pregnancy test perform monthly woman child-bearing potential ; study visit may do home . 8 . A plasma sample ( 3 mL ) collect stored baseline subject , use measurement darunavir trough ( pre-dose ) concentration subject receive darunavir pre-study regimen . 9 . All subject take study medication observation clinic Day 14 , plasma sample ( 3mL ) pharmacokinetic test drawn immediately pre-dose 1 , 2 , 3 , 4 , 5 , 6 , 8 hour post-dose . Subjects return follow day take Day 15 dose 24-hour post-dose sample . 10 . Peripheral blood mononuclear cell ( PBMCs ) collect stored baseline possible future study-related testing . 11 . The following questionnaire complete participant prior study procedure baseline week 24 48 : MOS-HIV quality life questionnaire ; HIVTSQ ; ACTG treatment adherence questionnaire ; medication adherence self-report inventory ( MASRI ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV positive adult &gt; = 19 year age receive stable therapy include one two nucleoside/nucleotide reverse transcriptase inhibitor ( NRTIs ) , conjunction oncedaily protease inhibitor ( PI ) ( atazanavir , lopinavir darunavir ) twice daily raltegravir daily dolutegravir Virologic suppression &gt; 6 month , define plasma viral load ( VL ) consistently &lt; 200 copies/mL evidence prior virologic rebound ( VL &gt; 1000 copies/mL ) NRTI/PI/Raltegravir regimen , AND VL &lt; 50 copies/mL time study screen Estimated glomerular filtration rate ( eGFR ) &gt; r= 70mL/min screen Prior document viral rebound &gt; 1000 copies/mL raltegravircontaining regimen Evidence resistance mutation compromise raltegravir elvitegravir activity prior genotype . Evidence clinically significant resistance tenofovir previous genotype test : K65R mutation , 3 thymidineanalogue associate mutation ( TAMS ) compromise tenofovir activity Evidence resistance mutation significantly compromise darunavir activity previous genotypic test Current use nonnucleoside reverse transcriptase inhibitor ( NNRTI ) Pregnancy breastfeed Contraindications tenofovir/FTC , elvitegravir , cobicistat ( e.g . previous significant toxicity , intolerance drug interaction</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>antiretroviral therapy</keyword>
</DOC>